Based on the current literature, clinical response to immunotherapy could be identified through IHC based on PDL-1, microsatellite instability (MSI), tumor mutational burden (TMB), T-cell receptor clonality, and the level of T-cell infiltration, as well as the expression of signature genes and peripheral blood biomarkers [31]. Here, CD274 is linked to neoplasm.